• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Solid Biosciences Inc. (SLDB) Stock Price, News & Analysis

Solid Biosciences Inc. (SLDB) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.41

$0.18

(3.44%)

Day's range
$5.21
Day's range
$5.62
50-day range
$4.61
Day's range
$8.1
  • Country: US
  • ISIN: US83422E2046
52 wk range
$2.63
Day's range
$15.05


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.86
  • Piotroski Score 2.00
  • Grade Overweight
  • Symbol (SLDB)
  • Company Solid Biosciences Inc.
  • Price $5.41
  • Changes Percentage (3.44%)
  • Change $0.18
  • Day Low $5.21
  • Day High $5.62
  • Year High $15.05

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/12/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $19.00
  • High Stock Price Target $20.00
  • Low Stock Price Target $12.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.93
  • Trailing P/E Ratio -2.05
  • Forward P/E Ratio -2.05
  • P/E Growth -2.05
  • Net Income $-96,015,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Solid Biosciences Inc. Frequently Asked Questions

  • What is the Solid Biosciences Inc. stock price today?

    Today's price of Solid Biosciences Inc. is $5.41 — it has increased by +3.44% in the past 24 hours. Watch Solid Biosciences Inc. stock price performance more closely on the chart.

  • Does Solid Biosciences Inc. release reports?

    Yes, you can track Solid Biosciences Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Solid Biosciences Inc. stock forecast?

    Watch the Solid Biosciences Inc. chart and read a more detailed Solid Biosciences Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Solid Biosciences Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Solid Biosciences Inc. stock ticker.

  • How to buy Solid Biosciences Inc. stocks?

    Like other stocks, SLDB shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Solid Biosciences Inc.'s EBITDA?

    Solid Biosciences Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Solid Biosciences Inc.’s financial statements.

  • What is the Solid Biosciences Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Solid Biosciences Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Solid Biosciences Inc.'s financials relevant news, and technical analysis. Solid Biosciences Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Solid Biosciences Inc. stock currently indicates a “sell” signal. For more insights, review Solid Biosciences Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.